louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05149794: Effects Of Calisthenic Exercises On Physical Fitness Among School Going Children
Official title: Effects Of Calisthenic Exercises On Physical Fitness Among School Going Children
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy Life Style
Physical Fitness
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2021-12-08
Enrollment: 48
Sex: MALE
Minimum age (years): 8
Maximum age (years): 13
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The study will be conducted to determine the effects of Calisthenic Exercise on Physical fitness among school going children .

Detailed description: Callisthenic Exercises has proven effective in gaining strength, endurance and balance in adults and children age (11 to 17 years) but still evidence is less as compared to children age (8 to 13 years). calesthenics can be perform in door so for children who mostly stay t home or on gadget if perform these activities may improve their physical fitness

Eligibility criteria: Inclusion Criteria:

* Male school going children (8-13 year of age)
* Participants who are able to perform 11-12 repetitions of Calisthenic Exercises mentioned in my Study.
* BMI of school going children (8-13 year of age)

Exclusion Criteria:

* • Children with any disability.

  * Children with any acute illness.
  * History of any fracture.

Primary outcomes:
measure: Euro fit Fitness Testing Battery
timeFrame: 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Islamabad
country: Pakistan
facility: Riphah international University
state: Federal
Study officials:
affiliation: Riphah International University
name: Waqar Ahmad Awan, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03619694: Role of MR Spectroscopy in Brain Tumors
Official title: Role of Magnetic Resonance Spectroscopy in Differentiating Brain Tumors
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Brain Neoplasms
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2018-08-08
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with brain tumors diagnosed by conventional imaging

Brief summary: In order to come as close as possible to the correct diagnosis of CNS tumors, MRI is the long-standing accepted method of choice that can in some cases be supported by the use of CT to demonstrate calcification or bone destruction. In individual cases MRI spectroscopy can be helpful for the differentiation between neoplasms and inflammatory lesions or surveillance of tumor therapy, just as perfusion

Detailed description: Proton magnetic resonance spectroscopy (H-MRS) may be helpful in suggesting tumor histology and tumor grade and may better define tumor extension and the ideal site for biopsy compared with conventional magnetic resonance (MR) imaging. A multifunctional approach with diffusion-weighted imaging, perfusion-weighted imaging, and permeability maps, along with H-MRS, may enhance the accuracy of the diagnosis and characterization of brain tumors and estimation of therapeutic response. Integration of advanced imaging techniques with conventional MR imaging and the clinical history help to improve the accuracy, sensitivity, and specificity in differentiating tumors and nonneoplastic lesions.

Eligibility criteria: Inclusion Criteria:

* All patients with space-occupying lesions

Exclusion Criteria:

* Post operative cases
* Non-neoplastic nature

Primary outcomes:
measure: Comparison of MRS findings with the pathology of the specimens
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Assiut University
Study officials:
References:
citation: Peitgen N, Papanagiotou P. [Intra-axial brain tumors in adults : On the basis of the 2016 WHO classification]. Radiologe. 2017 Sep;57(9):707-714. doi: 10.1007/s00117-017-0271-6. German.
citation: Brindle KM, Izquierdo-Garcia JL, Lewis DY, Mair RJ, Wright AJ. Brain Tumor Imaging. J Clin Oncol. 2017 Jul 20;35(21):2432-2438. doi: 10.1200/JCO.2017.72.7636. Epub 2017 Jun 22.
Clinical trial NCT06631794: Evaluation of the Impact of a HPV Vaccination Talk with Third Grade Students
Official title: Evaluation of the Impact of a HPV Vaccination Talk with Third Grade Students on Their Papillomavirus Vaccination Coverage.
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Teenagers
Lead sponsor: Hopital Foch
Sponsor class: OTHER
Collaborators: name: Agence Regionale de Sante d&#39;Ile de France
name: Ospharm coopérative
name: French Interregional Group of Clinical Research and Innovation
name: Communauté professionnelle territoriale de santé
First posted: 2024-10-08
Enrollment: 1170
Sex: ALL
Minimum age (years): 14
Maximum age (years): 14
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: 3rd grade students enrolled in public secondary schools in Suresnes and Rueil-Malmaison.

Brief summary: This is a prospective pragmatic study to assess the impact of a HPV vaccination talk in secondary school on actual vaccine dispensing in test communes compared with control communes. The talk consist on a briefing on the importance of vaccination.

This is a controlled study, since two communes will benefit from the HPV vaccination talk, while the other two will serve as controls without set up of the HPV vaccination talk. The set up of this presentation will be open-label.

Detailed description: The main aim of the present study is to investigate the impact of HPV vaccination talk with 3rd grade school children on HPV vaccine dispensing by making them actors in their own health. A significant benefit on vaccination coverage is expected. In addition, a flyer providing information and raising awareness of infections and the benefits of HPV vaccination will be sent to parents at the end of the talk.

Eligibility criteria: Inclusion Criteria:

* 3rd grade students enrolled in public secondary schools in Suresnes and Rueil-Malmaison.

Exclusion Criteria:

* Students absent on the day of the talk.
* Students unwilling/unable to complete questionnaire.

Primary outcomes:
measure: Impact Assessement of a sexual health talk with middle school students in 3rd grade on the dispensation of HPV vaccines among young people born in 2010.
timeFrame: 12 months preceding the talk and the 6 months following the talk
Secondary outcomes:
measure: 1rst Secondary outcoume
timeFrame: 8 weeks
measure: 2nd Secondary outcoume
timeFrame: 8 weeks
measure: 3rd secondary outcoume
timeFrame: 8 weeks
measure: 4 th secondary outcoume
timeFrame: 8 weeks
measure: 5 th secondary outcoume
timeFrame: 6 months after talk
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01468194: Change in Peripheral Oxygen Saturation by Using Different Breathing Procedures in High Altitude
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acute Mountain Sickness
Keywords: AMS
HAPE
high altitude
oxygen
saturation
mountain
climbing
breathing
Lead sponsor: University of Giessen
Sponsor class: OTHER
Collaborators: name: MVZ für Laboratoriumsmedizin Koblenz
First posted: 2011-11-09
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: In this investigation the researchers explore whether different types of breathing procedures can improve the peripheral oxygen saturation to reduce the risk of becoming a acute mountain sickness or a high altitude pulmonary edema.

Detailed description: Acute mountain sickness (AMS) is a pathological effect of high altitude on humans caused by acute exposure to low partial pressure of oxygen at high altitude. It commonly occurs above 2500 meters of altitude. AMS appears as a collection of nonspecific symptoms acquired at high altitude or in low air pressure resembling a case of "flu, carbon monoxide poisoning, or a hangover".

It is caused by a drop in pressure and lowering partial pressure of oxygen during increasing altitude. The direct consequence of those changes is a hypoxic pulmonary vasoconstriction (Euler-Lijestrand-mechanism). In addition a rise in pulmonary blood pressure (Hypertonia) can occur so that there is a higher risk of developing a high altitude pulmonary edema (HAPE).

In this investigation the investigators are exploring whether different types of breathing procedures can improve the peripheral oxygen saturation. We are comparing breathing with no regulation with two different procedures of hyperventilation during trekking in different altitudes. Procedure 1 (hyperventilation 1) describes inhalation during one step and exhalation during the next step. Procedure 2 (hyperventilation 2) describes inhalation and exhalation during one step.

The effect of the different breathing procedures can be quantified measuring the peripheral oxygen saturation. In addition the investigators are comparing the breathing rate and the minute ventilation as well as the expiratory end-tidal CO2-partial pressure of the three different breathing procedures.

Furthermore, the investigators are examining the ability to concentrate in order to quantify the effect of AMS on organ functions.

Eligibility criteria: Exclusion Criteria:

* acute clinically significant inter-current diseases

Primary outcomes:
measure: change of peripheral oxygen saturation
timeFrame: immediate after intervention
Secondary outcomes:
measure: change of breathing parameters
timeFrame: immediate after intervention
measure: change of cognition
timeFrame: immediate after intervention
Other outcomes:
Locations:
city: Giessen
country: Germany
facility: University of Giessen
state: Hessen
Study officials:
affiliation: Trauma surgery - University hospital Giessen
name: Gabor Szalay, Dr. med.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03034694: The Effect of Dermatology and Teledermatology Consultations on Length of Hospital Admission, 30 Day Readmission Rate, and Antibiotic Use in Patients Presenting With Cellulitis vs Pseudocellulitis in an Academic Inpatient Setting
Official title: The Effect of Dermatology and Teledermatology Consultations on Length of Hospital Admission, 30 Day Readmission Rate, and Antibiotic Use in Patients Presenting With Cellulitis vs Pseudocellulitis in an Academic Inpatient Setting
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cellulitis
Lead sponsor: Ohio State University
Sponsor class: OTHER
First posted: 2017-01-27
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Routine Care vs The use of teledermatology
Primary purpose: DIAGNOSTIC

Brief summary: The effect of teledermatology on length of hospital admission, length of stay, 30 day readmission rate, and antibiotic use in patients presenting with cellulitis vs pseudocellulitis in an academic emergency department setting.


Eligibility criteria: Inclusion Criteria:

* Over 18
* Admission for cellulitis-like symptoms, including but not limited to the following: tenderness, redness, swelling, expansive lesion

Exclusion Criteria:

* pregnant
* prisoner

Primary outcomes:
measure: Length of Hospitalization
timeFrame: 60 Days
Secondary outcomes:
measure: Readmission rate
timeFrame: 30 Days
measure: Frequency/Use of antibiotics
timeFrame: 30 days
Other outcomes:
Locations:
city: Columbus
country: United States
facility: The Ohio State University Wexner Medical Center
state: Ohio
Study officials:
affiliation: OSU Dermatology
name: Benjamin H Kaffenberger, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03618394: Bone Turnover and Parenteral Nutrition
Official title: Early Bone Turnover Markers in Relation to Parenteral Nutrition Regimens
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Bone Turnover Rate Disorder
Keywords: preterms
parenteral
lipid
Lead sponsor: Iaso Maternity Hospital, Athens, Greece
Sponsor class: OTHER
Collaborators: name: Harokopio University
name: National and Kapodistrian University of Athens
First posted: 2018-08-07
Enrollment: 66
Sex: ALL
Minimum age (years): 1
Maximum age (years): 3
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Very Low Birth Weight preterm neonates with gestational age \<32 weeks

Brief summary: Evaluation of changes in biochemical markers of bone metabolism. Fat profile. Evaluation of the overall body development. Assessment of parenteral nutrition protocols.

Detailed description: Osteopenia is very common in premature infants, particularly in preterm infants born at extremely low birth weight This is probably related to inadequate calcium and phosphorus intake, which is considerably less than the accretion of these minerals during the last trimester of pregnancy In addition, severe morbidity during the neonatal period (e.g. bronchopulmonary dysplasia \[BPD\]), chronic drug therapy (e.g. diuretics and systemic steroids), the need for total parenteral nutrition and prolonged immobility increase the risk of bone demineralization.

Total parenteral nutrition is associated with osteopenia in preterm infants. Insufficient calcium and phosphate are likely causes; aluminum contamination is another possible contributing factor as this adversely affects bone formation and mineralization.

The DHA+ARA-supplemented formulas supported normal growth and bone mineralization in premature infants who were born at \<33 wk gestation. Smof lipid emulsion has a high density of this fatty acids, while Intra lipid does not contain any traces of DHA. Evidence has shown that long-chain polyunsaturated fatty acids (LCPUFA), especially the ω-3 fatty acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are beneficial for bone health and turnover.

Eligibility criteria: Inclusion Criteria:

* gestational age \<32 weeks
* birth weight \<1500g (VLBW infants)
* in need of Parenteral Nutrition support

Exclusion Criteria:

* \>32 weeks of gestation
* chromosomal or other abnormalities
* parenteral nutrition \<80% of calorie/fluid needs
* primary liver disease

Primary outcomes:
measure: change in plasma calcium and osteocalcin levels
timeFrame: 20 days
Secondary outcomes:
measure: change in plasma DHA, EPA levels
timeFrame: 20 days
measure: cange in plasma OPG levels
timeFrame: 20 days
Other outcomes:
Locations:
city: Athens
country: Greece
facility: Panos Papandreou
Study officials:
References:
Clinical trial NCT05782894: Step 2 of A Two-step Trial to Evaluate the Effectiveness and Safety of Remimazolam Besylate for Sedation in ICU Patients
Official title: A Multicenter, Randomized, Single-blinded, Parallel, Two-step Trial to Evaluate the Effectiveness and Safety of Remimazolam Besylate for Injection for Sedation in ICU Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Sedative
Mechanical Ventilation
Lead sponsor: Wuhan Union Hospital, China
Sponsor class: OTHER
Collaborators: name: Yichang Humanwell Pharmaceutical Co., Ltd., China
First posted: 2023-03-24
Enrollment: 164
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A randomized non-inferior trial comparing remimazolam besylate with propofol for short-term sedation during invasive mechanical ventilation in intensive care units


Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 and ≤ 80 years
* Body mass index (BMI) ≥18 and ≤ 30 kg/m2
* Being Intubated and mechanically ventilated ≤48 hours before enrollment and expected to be on ventilator for at least 6 hours
* Requirement for light to moderate sedation (a Richmond agitation-sedation scale score of -2 to 1)

Exclusion Criteria:

* Refusal to be included
* Allergy or unsuitability to any composition of study drugs or remifentanil
* Living expectancy less than 48 hours
* Myasthenia gravis
* Status asthmaticus
* Abdominal compartment syndrome
* Serious hepatic dysfunction (CTP 10-15);
* Chronic kidney disease with glomerular filtration rate (GFR) \< 29 ml/min/1.73m2
* Mean blood pressure less than 65 mm Hg or the need of a continuous infusion of norepinephrine at ≥0.5 ug/kg/min to maintain Mean blood pressure ≥ 65 mm Hg
* Possible requirement for surgery or bedside tracheostomy in 24 hours
* Possible requirement for renal replacement therapy in 24 hours
* Acute severe neurological disorder and any other condition interfering with sedation assessment
* Abuse of controlled substances or alcohol
* Pregnancy or lactation
* Inclusion in another interventional trial in the past 30 days
* Other conditions deemed unsuitable to be included

Primary outcomes:
measure: Successful sedation
timeFrame: 24 hours
Secondary outcomes:
measure: The percentage of time in the target sedation range without rescue sedation
timeFrame: 24 hours
measure: Number of patients needing rescue sedation
timeFrame: 24 hours
measure: Number of patients needing repeated boluses of the study drug
timeFrame: 24 hours
measure: The amount of remifentanil in ug/kg/h
timeFrame: 24 hours
Other outcomes:
measure: Hypotension
timeFrame: 24 hours
measure: Delirium
timeFrame: 24 hours
Locations:
city: Wuhan
country: China
facility: Wuhan Union Hospital
state: Hubei
Study officials:
References:
Clinical trial NCT01349894: SNaP Wound Care System Over Skin Cancer Excision Sites and Split Thickness Skin Grafts (STSGs)
Official title: Post-Market Clinical Evaluation of the Spiracur SNaP™ Wound Care System for Treatment of Skin Cancer Excision Sites and Split Thickness Skin Grafts
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Split Thickness Skin Graft
Skin Cancer Excision Site
Skin Graft
Lead sponsor: Solventum US LLC
Sponsor class: INDUSTRY
Collaborators: name: 3M
First posted: 2011-05-09
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Study population will be selected from existing investigator patient population.

Brief summary: The purpose of this study is to evaluate the efficacy of the Spiracur SNaP® Wound Care System for the treatment of skin cancer excision sites and split thickness skin grafts (STSG). The secondary purpose will be to compare the prospective patients to retrospectively treated skin cancer excision sites and STSGs to further evaluate efficacy and safety.


Eligibility criteria: Inclusion Criteria:

* Skin cancer excision site and/or STSG as the source of the wound on any part of the body including head and neck, torso, and extremities. Any other type of skin graft will also be eligible for inclusion into the study.
* Wound \< 16 cm in greatest diameter
* Subject ≥ 18 years of age
* Female subjects of child-bearing potential must be willing to take a urine pregnancy test prior to starting study
* Subject is willing and able to sign informed consent

Exclusion Criteria:

* Wound-related cellulitis
* Wound located in an area not amenable to forming an air-tight seal
* Subject has untreated osteomyelitis
* Subject is allergic to wound care products
* Wound has exposed blood vessels not suitable for negative pressure therapy
* Subject is actively participating in other clinical trials that conflict with current study
* Subject has fistulas
* Subject is pregnant

Primary outcomes:
measure: Wound Closure
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Cleveland
country: United States
facility: Dermatology and Plastic Surgery Institute, Cleveland Clinic
state: Ohio
Study officials:
affiliation: The Cleveland Clinic
name: Francis Papay, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03320694: Comparison of Metformin and Insulin for Management of Gestational Diabetes Mellitus
Official title: Comparison of Metformin and Insulin for Management of Gestational Diabetes Mellitus
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Gestational Diabetes Mellitus in Pregnancy
Keywords: Gestational Diabetes Mellitus, Metformin, Insulin
Lead sponsor: Services Institute of Medical Sciences, Pakistan
Sponsor class: OTHER_GOV
First posted: 2017-10-25
Enrollment: 278
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Gestational diabetic mellitus (GDM) patients randomised to metformin or insulin group.Aim was to achieve blood sugar levels of Blood sugar fasting (BSF) \<5.3 mmol/l and 1 hour post meal\<7.8mmol/l. Both groups were followed till delivery and outcome studied.

Detailed description: 75 gm Oral Glucose Tolerance Test (OGTT) was done in pregnant patients. Blood sugar fasting(BSF) \> 5.5 mmol/l \& 2 hours postprandial \>7.8 mmol/l was labelled as GDM. They were randomised to metformin or insulin group. Those assigned to metformin group were started metformin 500mg twice daily \& increased until 2500mg depending on the blood sugar levels. Aim was to achieve blood sugar levels of BSF \<5.3 mmol/l and 1 hour post meal\<7.8mmol/l. If blood sugar levels were not controlled, insulin was added. The insulin group was given 3 injections of regular insulin \& one intermediate acting insulin injection at night subcutaneously. Both groups were followed till delivery and outcome studied

Eligibility criteria: Inclusion Criteria:•

* All pregnant Diagnosed GDM in pregnancy by OGTT from 22 week to 34 week with singleton pregnancy

Exclusion Criteria:

* Patients with Known diabetes mellitus
* Patients with multiple pregnancy
* With essential hypertension or pre eclampsia
* Patients having fetal malformation incompatible with life
* Patients with intrauterine death of fetus

Primary outcomes:
measure: maternal glycemic control
timeFrame: From time of randomisation till 40 weeks
Secondary outcomes:
measure: Fetal macrosomia
timeFrame: at birth
measure: Apgar score
timeFrame: at birth
measure: Neonatal intensive care unit (NICU) stay
timeFrame: >24 hours after birth
measure: Perinatal death
timeFrame: 7 days of delivery
measure: mode of delivery
timeFrame: at delivery
measure: Neonatal hypoglycemia
timeFrame: at birth
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: Services Institute of Medical Sciences
state: Punjab
Study officials:
References: